Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Biotin Sublingual Spray and Melatonin Sublingual Spray to help consumers tackle health issues that come with today’s fast-paced life
Poor oral health (periodontal disease) impacts nearly 51% of Indians
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
Subscribe To Our Newsletter & Stay Updated
